Q&A

Exclusive interviews with industry leaders


  • story image
    Image attribution tooltip
    Stock via Getty Images

    The UK-based company that's striving to overcome the limitations of T cell receptor innovation

    Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

    Kim Ribbink • May 23, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    Ironwood Pharmaceuticals is charting a course to become a giant in GI

    Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market. 

    Karissa Waddick • May 19, 2022
  • story image
    Image attribution tooltip
    Spencer Platt via Getty Images

    BriOri BioTech sets the stage for the comeback of Vioxx

    With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

    Kelly Bilodeau • May 17, 2022
  • story image
    Image attribution tooltip
    Natali_Mis via Getty Images

    Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

    Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

    Michael Gibney • May 17, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

    With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

    Taren Grom • May 9, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    One company's failed drug is this company's 'jewel'

    Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

    Meagan Parrish • May 2, 2022
  • story image
    Image attribution tooltip

    Permission granted by Alan Millar. 

    How an open platform can shake up the drug development process

    TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

    Kim Ribbink • April 28, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    Kelly Bilodeau • April 26, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    How OliX Pharmaceuticals is riding the RNAi wave

    While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

    Karissa Waddick and Taren Grom • April 25, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    The cannabis vanguard: A rare disease company looks to pioneer in the space

    Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

    Jared Whitlock • April 21, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

    Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

    Alexandra Pecci • April 21, 2022
  • story image
    Image attribution tooltip
    Justin Sullivan / Staff via Getty Images

    How pharma can up its social media game

    Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities. 

    Karissa Waddick • April 18, 2022
  • story image
    Image attribution tooltip
    Yongyuan via Getty Images

    Biotech goes Hollywood

    A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

    Taren Grom • April 13, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Down but not out: How AVEO's CEO steered the company past an FDA rejection

    Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

    Kim Ribbink • April 5, 2022
  • story image
    Image attribution tooltip
    Real Chemistry/PharmaVoice

    Lessons from improv: Shankar Narayanan's 'yes, and' approach to healthcare leadership

    Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

    Taren Grom • April 4, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Time-saving tech lights Alcon's path into digital innovation

    Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

    Kim Ribbink • April 4, 2022
  • story image
    Image attribution tooltip

    Sangamo Therapeutics

    Sangamo has its finger on the next evolution of gene editing

    Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

    Taren Grom • March 31, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Rare Patient Voice's president is striving to create a five-star experience for patients

    Successful clinical trial recruitment depends on listening to and empowering patients.

    Kim Ribbink • March 23, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Why Astellas is adopting a 'focus area approach' to partnerships

    Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

    Kim Ribbink • March 22, 2022
  • story image
    Image attribution tooltip
    Retrieved from PharmaVOICE on March 21, 2022

    BioMarin's new global head of advocacy is tackling the holy grail of patient engagement

    In her new role, Dr. Roz is keeping her patient-first approach.

    Taren Grom • March 21, 2022
  • story image
    Image attribution tooltip

    Novartis' manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. Permission granted by Novartis.

    How Novartis kept its supply chain intact during COVID-19

    In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability. 

    Taren Grom • March 16, 2022
  • story image
    Image attribution tooltip

    Image courtesy of Medigene.

    Medigene's CEO on striking a collaboration deal with BioNTech

    The two companies recently announced a $29 million collaboration. 

    Jared Whitlock • March 15, 2022
  • story image
    Image attribution tooltip

    Permission granted by Sanjeev Luther.

    Clearing hurdles in rare cancer drug development

    Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

    Kim Ribbink • March 14, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

    The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

    Taren Grom • March 14, 2022
  • story image
    Image attribution tooltip
    Permission granted by Terry Weber

    Biote CEO: Employers need to normalize women's health issues in the workforce

    A survey by Biote reveals the impact of menopause on working women.

    Robin Robinson • March 14, 2022